Effects of two continuous hormone therapy regimens on C-reactive protein and homocysteine

@article{Barnes2005EffectsOT,
  title={Effects of two continuous hormone therapy regimens on C-reactive protein and homocysteine},
  author={Judith F Barnes and Elizabeth Farish and Marion Rankin and David M Hart},
  journal={Menopause},
  year={2005},
  volume={12},
  pages={92-98}
}
Objective: To compare the effects of two continuous hormone therapy (HT) regimens on the cardiovascular risk markers, C-reactive protein (CRP) and homocysteine. Design: A prospective study in which 43 postmenopausal women were randomly assigned to either tibolone 2.5 mg/day (n = 20) or 0.625 mg/day conjugated equine estrogens (CEE) plus continuous medroxyprogesterone acetate (MPA) 5 mg/day (n = 23). Serum levels of CRP, homocysteine, vitamin B12, and folate were determined before and during 12… Expand
THE EFFECTS OF TIBOLONE ON RISK FACTORS OF CARDIOVASCULAR DISEASE IN MENOPAUSAL WOMEN
Background: Tibolone is frequently used as a hormone-like alternative to traditional HRT. Therefore, it is valuable to compare the effects of tibolone and HRT on cardiovascula r diseases riskExpand
The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors
TLDR
The effect of tibolone on fibrinolysis and triglycerides suggests that tibolin has a favorable pharmacological profile on these risk factors when compared to CEE/MPA, which has comparable effects on most metabolic risk factors investigated. Expand
Differential impact of conventional‐dose and low‐dose postmenopausal hormone therapy, tibolone and raloxifene on C‐reactive protein and other inflammatory markers
TLDR
The average increase in CRP was not accompanied by increases in the average levels of IL‐6, TNF‐α or other markers, but women with large reductions in IL‐ 6 had reduced increases inCRP. Expand
Short-term effect of tibolone on C-reactive protein in hypertensive postmenopausal women
TLDR
It is demonstrated that tibolone treatment induced a significant increase in CRP and a significant decrease in total cholesterol in postmenopausal hypertensive women. Expand
Effects of menopause and tibolone on different cardiovascular biomarkers in healthy women
TLDR
As menopause is associated with increased blood pressure, inflammation and oxidative stress, tibolone restores blood pressure and has beneficial effect on inflammation and glycemia without worsening oxidative stress- although it also reduces HDL levels. Expand
The effects of raloxifene and tibolone on homocysteine and vascular histopathological changes
TLDR
The view that neither RLX nor TBN appears to have a primary protective effect on vascular disease by effecting the metabolism of Hcy at menopause is supported. Expand
Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women.
TLDR
The data suggest that oral estrogen induces ASVD risk by increasing acute inflammation; however, transdermal estrogen avoids this untoward effect and the transDermal route might be favourable in terms of ASVD risks. Expand
Effects of hormone treatment on hemostasis variables
  • C. Kluft
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2007
TLDR
It was concluded that unopposed, non-oral estrogen treatment is the present best available option approaching minimal effects of treatment on biomarkers, and minimal effects on all cardiovascular biomarkers should define the HT with maximal safety for venous and arterial vascular events. Expand
Long-term effects of tibolone on circulating levels of vascular cell adhesion molecules and E-selectin in postmenopausal women.
TLDR
Tibolone induces favorable changes in endothelial function and may exert a direct cardiovascular protective effect in postmenopausal women. Expand
Estrogen, medroxyprogesterone acetate, endothelial function, and biomarkers of cardiovascular risk in young women.
TLDR
It is suggested that acute MPA administration negates the beneficial effects of estradiol on endothelium-dependent vasodilation in young women and that the addition of MPA may counteract the effect of est radiol on endothelin-1. Expand
...
1
2
...

References

SHOWING 1-10 OF 75 REFERENCES
Effect of hormone replacement therapy and tibolone on serum total homocysteine levels in postmenopausal women.
TLDR
Continuous CEE/MPA reduces tHcy especially in women with high pretreatment tH Cy levels, and Tibolone has no effect on serum tHCy levels at least during the first 18 months of therapy. Expand
A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors.
TLDR
Results indicate that tibolone may have a more favourable effect on cardiovascular risk than previously suggested, and the reduction in LDL induced by the continuous combined therapy is likely to be beneficial, despite the apparent shift towards the LDLIII subfraction. Expand
The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial.
TLDR
HRT and raloxifene lower serum homocysteine levels to a comparable extent in postmenopausal women, and the relationship between elevated C-reactive protein levels with HRT and cardiovascular disease events requires further study. Expand
Effects of tibolone on plasma homocysteine levels in postmenopausal women.
TLDR
Despite the reported beneficial effect of tIBolone on the serum lipid profile, tibolone had no statistically significant effect on serum homocysteine levels in postmenopausal women. Expand
Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations.
TLDR
HRT resulted in a significant increase in CRP concentrations in the women receiving the continuous combination of E2V plus norethindrone acetate and the continuous regimen of E 2V plus local delivery of levonorgestrel, and both the estrogen and the progestin component are of importance for the change. Expand
Hormone replacement therapy and increased plasma concentration of C-reactive protein.
TLDR
In this cross-sectional survey, CRP levels were increased among apparently healthy postmenopausal women taking HRT, and the potential impact of HRT on inflammatory parameters should be investigated in ongoing clinical trials. Expand
Effect of long-term hormone replacement therapy on plasma homocysteine in postmenopausal women: a randomized controlled study.
TLDR
Long-term hormone replacement therapy results in lower total homocysteine concentrations in all methylenetetrahydrofolate reductase genotypes without demonstrable difference in effect between unopposed and opposed hormone Replacement therapy. Expand
Effects of tibolone and combined 17beta-estradiol and norethisterone acetate on serum C-reactive protein in healthy post-menopausal women: a randomized trial.
TLDR
Tibolone and E(2) + NETA significantly increase serum CRP levels in healthy post-menopausal women to a comparable extent and relationships between induced elevatedCRP levels with tibol one and E (2) - NETA and cardiovascular events require further studies. Expand
Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen.
TLDR
The effects of oral estrogen and transdermal estradiol on Creactive protein plasma levels in healthy postmenopausal women are compared. Expand
Increased Levels of C-Reactive Protein After Oral Hormone Replacement Therapy May Not Be Related to an Increased Inflammatory Response
TLDR
The discrepancy between increased Plasma levels of CRP and reduced plasma levels of all other markers of inflammation suggests that the increased CRP levels after oral HRT may be related to metabolic hepatic activation and not to an acute-phase response. Expand
...
1
2
3
4
5
...